Loading...
•
Jun 30, 2024
Paysign Q2 2024 Earnings Report
Paysign's second-quarter financial results reflected substantial revenue growth and increased profitability.
Key Takeaways
Paysign reported a strong second quarter with a 29.8% increase in revenue and a 95.8% increase in adjusted EBITDA. Growth was driven by the plasma donor compensation business and the patient affordability business. The company is raising its full-year guidance due to this outperformance.
Revenues grew by 29.8% year-over-year.
Adjusted EBITDA increased by 95.8% year-over-year.
Gross margin percentage increased by 207 basis points.
Full-year revenue guidance was raised.
Revenue by Segment
Forward Guidance
Paysign raised its full year 2024 guidance, expecting total revenues between $56.5 million and $58.5 million, gross profit margins between 54.0% and 55.0%, operating expenses between $30.0 million and $32.0 million, interest income between $3.0 million and $3.2 million, a tax rate between 28.0% and 29.0%, and net income between $2.0 million and $3.0 million.
Positive Outlook
- Total revenues are estimated to be in the range of $56.5 million to $58.5 million.
- Plasma revenues are estimated to account for approximately 78% of total revenue.
- Pharma revenue is estimated to account for approximately 20% of total revenue.
- Full-year gross profit margins are expected to be between 54.0% and 55.0%.
- Interest income of $3.0 million to $3.2 million expected.
Challenges Ahead
- Operating expenses are expected to be between $30.0 million and $32.0 million.
- Tax rate to be between 28.0% and 29.0%.
- Fully diluted share count outstanding to be 55.8 million to 56.0 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...